Literature DB >> 25865485

Motor neuron disease-frontotemporal dementia: a clinical continuum.

Emma Devenney1, Steve Vucic, John R Hodges, Matthew C Kiernan.   

Abstract

Overlap between motor neuron disease (MND) and frontotemporal dementia (FTD) occurs at clinical, genetic and pathological levels, and has been recently strengthened through the discovery of the C9orf72 genetic expansion. MND is now considered to be a multisystem disorder in which cognitive involvement may be present and, in some cases, may evolve to frank FTD. Identifying cognitive features in MND can be challenging, while, similarly, motor dysfunction in FTD may be overlooked. As such, the present review aims to decipher the variety of overlapping clinical features across the MND-FTD continuum.

Entities:  

Keywords:  C9orf72; Frontotemporal dementia; behavior; clinical continuum; cognition; genetics; motor neuron disease; neuroimaging; neurophysiology

Mesh:

Substances:

Year:  2015        PMID: 25865485     DOI: 10.1586/14737175.2015.1034108

Source DB:  PubMed          Journal:  Expert Rev Neurother        ISSN: 1473-7175            Impact factor:   4.618


  17 in total

1.  Comparative analysis of C9orf72 and sporadic disease in an ALS clinic population.

Authors:  Mfon E Umoh; Christina Fournier; Yingjie Li; Meraida Polak; Latoya Shaw; John E Landers; William Hu; Marla Gearing; Jonathan D Glass
Journal:  Neurology       Date:  2016-08-03       Impact factor: 9.910

Review 2.  A clinicopathological approach to the diagnosis of dementia.

Authors:  Fanny M Elahi; Bruce L Miller
Journal:  Nat Rev Neurol       Date:  2017-07-14       Impact factor: 42.937

3.  Primary progressive aphasia and the FTD-MND spectrum disorders: clinical, pathological, and neuroimaging correlates.

Authors:  Giulia Vinceti; Nicholas Olney; Maria Luisa Mandelli; Salvatore Spina; H Isabel Hubbard; Miguel A Santos-Santos; Christa Watson; Zachary A Miller; Catherine Lomen-Hoerth; Paolo Nichelli; Bruce L Miller; Lea T Grinberg; William W Seeley; Maria Luisa Gorno-Tempini
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2019-01-22       Impact factor: 4.092

Review 4.  Pharmacotherapy for Frontotemporal Dementia.

Authors:  Rita Khoury; Yu Liu; Quratulanne Sheheryar; George T Grossberg
Journal:  CNS Drugs       Date:  2021-04-11       Impact factor: 5.749

Review 5.  C9orf72's Interaction with Rab GTPases-Modulation of Membrane Traffic and Autophagy.

Authors:  Bor L Tang
Journal:  Front Cell Neurosci       Date:  2016-10-07       Impact factor: 5.505

6.  Protein Quality Control and the Amyotrophic Lateral Sclerosis/Frontotemporal Dementia Continuum.

Authors:  Hamideh Shahheydari; Audrey Ragagnin; Adam K Walker; Reka P Toth; Marta Vidal; Cyril J Jagaraj; Emma R Perri; Anna Konopka; Jessica M Sultana; Julie D Atkin
Journal:  Front Mol Neurosci       Date:  2017-05-10       Impact factor: 5.639

7.  Schizotypal traits across the amyotrophic lateral sclerosis-frontotemporal dementia spectrum: pathomechanistic insights.

Authors:  Nga Yan Tse; Sicong Tu; Yu Chen; Jashelle Caga; Carol Dobson-Stone; John B Kwok; Glenda M Halliday; Rebekah M Ahmed; John R Hodges; Olivier Piguet; Matthew C Kiernan; Emma M Devenney
Journal:  J Neurol       Date:  2022-03-13       Impact factor: 6.682

8.  Frequency and risk factor analysis of cognitive and anxiety-depressive disorders in patients with amyotrophic lateral sclerosis/motor neuron disease.

Authors:  Fang Cui; Wenjia Zhu; Zhibin Zhou; Yuting Ren; Yifan Li; Mao Li; Yunyun Huo; Xusheng Huang
Journal:  Neuropsychiatr Dis Treat       Date:  2015-11-03       Impact factor: 2.570

9.  Designing an Internationally Accessible Web-Based Questionnaire to Discover Risk Factors for Amyotrophic Lateral Sclerosis: A Case-Control Study.

Authors:  Jane Alana Parkin Kullmann; Susan Hayes; Min-Xia Wang; Roger Pamphlett
Journal:  JMIR Res Protoc       Date:  2015-08-03

Review 10.  From basic research to the clinic: innovative therapies for ALS and FTD in the pipeline.

Authors:  Rajka Maria Liscic; Antonella Alberici; Nigel John Cairns; Maurizio Romano; Emanuele Buratti
Journal:  Mol Neurodegener       Date:  2020-06-01       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.